AACR 2024: BCG017, a bispecific ADC targeting PTK7 and EGFR exhibits anti-tumor efficacy in PDX models
Used in the poster: Bispecific ADC Platform
Summary:
A bispecific antibody-drug conjugate (bsADC), BCG017-vcMMAE, targeting both PTK7 and EGFR demonstrated potent anti-tumor activity in various cancer models. This bsADC showed high binding and internalization in vitro, suggesting improved tumor selectivity. Surprisingly, BCG017-vcMMAE exhibited enhanced efficacy compared to benchmarks and parental ADCs in patient-derived xenograft (PDX) models with low PTK7 expression, indicating potential benefits in heterogeneous tumors expressing both PTK7 and EGFR. Further development with topoisomerase I inhibitors (TOP1i) conjugates is ongoing.
